INT13507

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.77
First Reported 1991
Last Reported 2008
Negated 5
Speculated 1
Reported most in Body
Documents 17
Total Number 28
Disease Relevance 34.23
Pain Relevance 7.58

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Erbb2) plasma membrane (Erbb2) nucleus (Erbb2)
DNA binding (Erbb2) cytoplasm (Erbb2)
Anatomy Link Frequency
neuron 2
SNU-1 2
spinal cord 1
Erbb2 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
qutenza 28 100.00 Very High Very High Very High
Chronic pancreatitis 66 99.12 Very High Very High Very High
Spinal cord 3 99.00 Very High Very High Very High
fibrosis 15 97.36 Very High Very High Very High
palliative 2 91.28 High High
Pain 6 85.72 High High
medulla 22 84.88 Quite High
cytokine 2 75.00 Quite High
methotrexate 2 74.40 Quite High
Enkephalin 2 72.48 Quite High
Disease Link Frequency Relevance Heat
Cancer 307 100.00 Very High Very High Very High
Hyperplasia 9 99.92 Very High Very High Very High
Malignant Neoplastic Disease 408 99.84 Very High Very High Very High
Breast Cancer 65 99.84 Very High Very High Very High
Pancreatic Cancer 8 99.66 Very High Very High Very High
Pheochromocytoma 561 99.48 Very High Very High Very High
Pancreatitis 106 99.44 Very High Very High Very High
Male Breast Neoplasms 6 98.88 Very High Very High Very High
Disease 35 98.64 Very High Very High Very High
Metastasis 13 98.28 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
IHC analysis of ERBB-2 further confirmed that the expression of ERBB-2 in malignant tumors was much higher than that in the benign ones, whereas no ERBB-2 protein expression was found in normal tissues.
Gene_expression (expression) of ERBB-2 associated with malignant neoplastic disease
1) Confidence 0.77 Published 2008 Journal Endocrine-Related Cancer Section Body Doc Link PMC2254511 Disease Relevance 1.66 Pain Relevance 0
Overexpression of the ERBB-2, a breast cancer marker, is associated with rapid tumor growth, increased risk of recurrence after surgery, poor response to conventional chemotherapy, and shortened survival, and this ERBB-2 overexpression has also been implicated in the neoplastic transformation of prostate cancer (Ross & Fletcher 1998, Yu et al. 1998).
Gene_expression (Overexpression) of ERBB-2 associated with cancer, breast cancer, prostate cancer and recurrence
2) Confidence 0.77 Published 2008 Journal Endocrine-Related Cancer Section Body Doc Link PMC2254511 Disease Relevance 1.14 Pain Relevance 0
Overexpression of ERBB-2 was more frequently detected in malignant than benign pheochromocytomas by multiplex ligation-dependent probe amplification and immunohistochemistry

To analyze the genetic alterations of pheochromocytomas and evaluate the difference among malignant, extra-adrenal, and benign pheochromocytomas.

Gene_expression (Overexpression) of ERBB-2 associated with malignant neoplastic disease and pheochromocytoma
3) Confidence 0.77 Published 2008 Journal Endocrine-Related Cancer Section Title Doc Link PMC2254511 Disease Relevance 1.18 Pain Relevance 0
IHC analysis of ERBB-2 further confirmed that the expression of ERBB-2 in malignant tumors was much higher than that in the benign ones, whereas no ERBB-2 protein expression was found in normal tissues.
Neg (no) Gene_expression (expression) of ERBB-2 associated with malignant neoplastic disease
4) Confidence 0.77 Published 2008 Journal Endocrine-Related Cancer Section Body Doc Link PMC2254511 Disease Relevance 1.62 Pain Relevance 0
Overexpression of the ERBB-2, a breast cancer marker, is associated with rapid tumor growth, increased risk of recurrence after surgery, poor response to conventional chemotherapy, and shortened survival, and this ERBB-2 overexpression has also been implicated in the neoplastic transformation of prostate cancer (Ross & Fletcher 1998, Yu et al. 1998).
Gene_expression (overexpression) of ERBB-2 associated with cancer, breast cancer, prostate cancer and recurrence
5) Confidence 0.77 Published 2008 Journal Endocrine-Related Cancer Section Body Doc Link PMC2254511 Disease Relevance 1.24 Pain Relevance 0
ErbB2 oncogene expression supports the acute pancreatitis-chronic pancreatitis sequence.
Gene_expression (expression) of ErbB2 associated with pancreatitis and chronic pancreatitis
6) Confidence 0.70 Published 2002 Journal Virchows Arch. Section Title Doc Link 12404064 Disease Relevance 1.47 Pain Relevance 0.72
Since in our previous studies the expression of two anti-ErbB2 growth factor receptor (ErbB2) antibodies was shown to discriminate between primary chronic pancreatitis, normal tissue, and secondary chronic pancreatitis caused by pancreatic cancer, we studied the ErbB2 expression in tissues obtained from acute, recurrent acute, and chronic pancreatitis to investigate a possible evolution of the ErbB2 expression pattern during the course of the disease.
Gene_expression (expression) of ErbB2 associated with pancreatic cancer, disease and chronic pancreatitis
7) Confidence 0.70 Published 2002 Journal Virchows Arch. Section Abstract Doc Link 12404064 Disease Relevance 1.65 Pain Relevance 0.80
Since in our previous studies the expression of two anti-ErbB2 growth factor receptor (ErbB2) antibodies was shown to discriminate between primary chronic pancreatitis, normal tissue, and secondary chronic pancreatitis caused by pancreatic cancer, we studied the ErbB2 expression in tissues obtained from acute, recurrent acute, and chronic pancreatitis to investigate a possible evolution of the ErbB2 expression pattern during the course of the disease.
Gene_expression (expression) of ErbB2 associated with pancreatic cancer, disease and chronic pancreatitis
8) Confidence 0.70 Published 2002 Journal Virchows Arch. Section Abstract Doc Link 12404064 Disease Relevance 1.54 Pain Relevance 0.79
Since in our previous studies the expression of two anti-ErbB2 growth factor receptor (ErbB2) antibodies was shown to discriminate between primary chronic pancreatitis, normal tissue, and secondary chronic pancreatitis caused by pancreatic cancer, we studied the ErbB2 expression in tissues obtained from acute, recurrent acute, and chronic pancreatitis to investigate a possible evolution of the ErbB2 expression pattern during the course of the disease.
Spec (investigate) Gene_expression (expression) of ErbB2 associated with pancreatic cancer, disease and chronic pancreatitis
9) Confidence 0.70 Published 2002 Journal Virchows Arch. Section Abstract Doc Link 12404064 Disease Relevance 1.72 Pain Relevance 0.85
Since in our previous studies the expression of two anti-ErbB2 growth factor receptor (ErbB2) antibodies was shown to discriminate between primary chronic pancreatitis, normal tissue, and secondary chronic pancreatitis caused by pancreatic cancer, we studied the ErbB2 expression in tissues obtained from acute, recurrent acute, and chronic pancreatitis to investigate a possible evolution of the ErbB2 expression pattern during the course of the disease.
Gene_expression (expression) of ErbB2 associated with pancreatic cancer, disease and chronic pancreatitis
10) Confidence 0.70 Published 2002 Journal Virchows Arch. Section Abstract Doc Link 12404064 Disease Relevance 1.53 Pain Relevance 0.78
Further studies proved that ERBB-2 gene product is a 185?
Gene_expression (product) of ERBB-2
11) Confidence 0.67 Published 2008 Journal Endocrine-Related Cancer Section Body Doc Link PMC2254511 Disease Relevance 1.18 Pain Relevance 0
We observed that expression of NRG1 mRNA and the neuregulin receptors, ErbB2 and ErbB4 in the lumbar spinal cord was facilitated by the presence of progesterone in female rats following L5 nerve root ligation.
Gene_expression (expression) of ErbB2 in spinal cord associated with spinal cord
12) Confidence 0.63 Published 2008 Journal Eur J Pain Section Abstract Doc Link 17459743 Disease Relevance 0.07 Pain Relevance 0.38
The Kruskal–Wallis test showed significantly higher ERBB-2 oncoprotein expression in the malignant pheochromocytomas (P=0.0065, K–W test; Table 3).


Gene_expression (expression) of ERBB-2 associated with malignant neoplastic disease and pheochromocytoma
13) Confidence 0.60 Published 2008 Journal Endocrine-Related Cancer Section Body Doc Link PMC2254511 Disease Relevance 2.00 Pain Relevance 0.04
The overexpression of ERBB-2 identified by IHC suggested that this oncogene could be associated with the malignancy of pheochromocytomas and paragangliomas.



Gene_expression (overexpression) of ERBB-2 associated with malignant neoplastic disease, paraganglioma and pheochromocytoma
14) Confidence 0.60 Published 2008 Journal Endocrine-Related Cancer Section Abstract Doc Link PMC2254511 Disease Relevance 1.49 Pain Relevance 0
To study the expression of ERBB-2 oncogene in pheochromocytomas, we further analyzed 39 out of the 43 samples by IHC analysis.
Gene_expression (expression) of ERBB-2 associated with pheochromocytoma
15) Confidence 0.60 Published 2008 Journal Endocrine-Related Cancer Section Body Doc Link PMC2254511 Disease Relevance 1.59 Pain Relevance 0
The frequency of cells expressing the ERBB-2 protein differed among tumors.
Gene_expression (expressing) of ERBB-2 associated with cancer
16) Confidence 0.60 Published 2008 Journal Endocrine-Related Cancer Section Body Doc Link PMC2254511 Disease Relevance 1.56 Pain Relevance 0.03
Breast carcinoma tissue, known to express the ERBB-2 protein, was used as the positive control.
Gene_expression (express) of ERBB-2 associated with breast cancer
17) Confidence 0.60 Published 2008 Journal Endocrine-Related Cancer Section Body Doc Link PMC2254511 Disease Relevance 0.21 Pain Relevance 0
The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer.
Gene_expression (value) of C-erb B-2 associated with colon cancer
18) Confidence 0.17 Published 1995 Journal Ann. Oncol. Section Title Doc Link 8573538 Disease Relevance 0.19 Pain Relevance 0.09
Consequently, SNU-1 cells are sensitive to CAP in the overexpression of tumor suppressor gene, p53 and proto-oncogenes, c-myc and c-Ha-ras, but not those of c-erbB-2, c-jun and bcl-2 genes.
Gene_expression (those) of c-erbB-2 in SNU-1 associated with qutenza and cancer
19) Confidence 0.09 Published 1997 Journal Cancer Lett. Section Abstract Doc Link 9461043 Disease Relevance 1.18 Pain Relevance 0.99
Consequently, SNU-1 cells are sensitive to CAP in the overexpression of tumor suppressor gene, p53 and proto-oncogenes, c-myc and c-Ha-ras, but not those of c-erbB-2, c-jun and bcl-2 genes.
Neg (not) Gene_expression (sensitive) of c-erbB-2 in SNU-1 associated with qutenza and cancer
20) Confidence 0.09 Published 1997 Journal Cancer Lett. Section Abstract Doc Link 9461043 Disease Relevance 1.21 Pain Relevance 1.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox